reason report
bottom line maintain op rate lower pt
estim slower near-term treatment growth
less opportun cost per treatment improv face
delay de novo open lower treatment growth outlook
near-term compani proactiv address growth
headwind work third-parti contractor
acceler open lower reimburs op contract
remain headwind potenti pressur
payor though could volum upsid reflect
estim cost-per-treat improv mircera
ytd believ use cash flow build-out de novo clinic
mainten capital-expenditure debt paydown ebitda less
nci lower mm mm respect
revenu ebitda less nci modest miss
expect ramp treatment growth de novo
expect revenu miss consensu ebitda less
nci mm versu consensu estim mm
cost-per-treat face headwind elev cost
employe health plan expens network revenue-
per-treat headwind compani posit
long-term prospect potenti volum gain ep beat
consensu exhibit
treatment outlook lower bp near-term due
time de novo ramp plan de novo
open de novo open delay due
receiv medicar certif survey due backlog
shortag construct contractor activ address
certif headwind work contractor
begin receiv certif acceler de
novo open de novo pipelin remain solid consist
deal estim treatment growth normal basi net
divestitur near bottom end guidanc exhibit
lower reimburs network remain
headwind though manag posit potenti
volum improv believ mm headwind
estim conserv includ upsid volum
improv contract though could price
pressur commerci payor go network
ev ebitda multipl
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
net revenu mm
pleas refer page import disclosur price chart analyst certif
solid medicar rate updat revenu tailwind
propos solid vs preliminari rate increas esrd
end stage renal diseas freestand facil rate compar
final rate propos rate exhibit
esa transit aranesp mircera annual benefit
expect becom appar add one year tailwind
calcimimet also posit impact ebitda exhibit
ebitda expect low end guidanc
mm due lower treatment growth expect health plan
headwind vs estim consensu mm time
report guidanc contempl potenti upsid
sensipar current gener market
lower estim lower ebitda
less nci mm low end guidanc reflect slower
ramp treatment growth increas health plan expens
lower ebitda less nci mm assum
volum upsid contract may conserv
cffo yoy due time work capit
settlement posit leverag improv ytd
believ elimin legal expens treatment growth
lead acceler capit invest leverag reduct
capit deploy focus larg build-out de novo clinic
mainten debt paydown exhibit
lower pt pt contempl
maintain op rate lower pt estim slower
near-term treatment growth less opportun cost per treatment improv
face delay de novo open lower treatment growth outlook
near-term compani proactiv address growth headwind work
third parti contractor acceler open lower reimburs
contract remain headwind potenti pressur payor though
could volum upsid reflect estim per treatment
improv mircera calcimimet offer one year tailwind reduc leverag
ytd believ use cash flow build-out de novo clinic mainten capital-expenditure
debt paydown ebitda less nci lower mm mm
revenu ebitda less nci modest miss expect ramp treatment
growth de novo expect revenu miss consensu ebitda less
nci mm versu consensu estim mm per treatment face
headwind elev cost employe health plan expens network
revenu per treatment headwind compani posit long-term
prospect potenti volum gain ep beat consensu
treatment outlook lower bp near-term due time de novo
ramp plan de novo open de novo open
delay due receiv medicar certif survey due backlog
shortag construct contractor activ address certif
headwind work contractor begin receiv certif
acceler de novo open de novo pipelin remain solid consist
deal estim treatment growth normal basi net divestitur
near bottom end guidanc
lower reimburs network remain headwind though
manag posit potenti volum improv believ
mm headwind estim conserv includ upsid volum
improv contract though could price pressur
commerci payor go network
solid medicar rate updat revenu tailwind propos solid vs
preliminari rate increas esrd freestand facil rate compar
final rate propos rate
esa transit aranesp mircera annual benefit expect becom
appar add one-year tailwind calcimimet also posit impact
hospit ipp rate updat net increas propos final propos final propos final propos final propos final propos final american renal associ hold inc
mircera epo altern pois gener save acceler
continu make solid progress expens side adopt esa altern
mircera septemb physician chosen convert mircera primari esa nearli
two-third clinic base strong physician interest long-act esa still expect
physician clinic convert mircera year-end
joseph carlucci chairman ceo co-found
think say two-third clinic convert mircera typic patient within
clinic convert doctor choic case true think could roughli
say two-third treatment mircera
think said clarifi low-singl dollar per treatment cost save mircera
someth reconfirm plan mircera turn pretti plan
year still expect exit year physician adopt
mircera say certainli benefit call relat employe health
benefit cost varianc approxim year-to-d sort take low-singl
dollar benefit talk essenti off-set unfortun trend
continu expect calcimimet posit transit
medicar environ calcimimet expect dynam due addit coverag
non-medicar payer introduct gener version sensipar chang practic pattern
respect iv drug parsabiv oral drug sensipar clinician gain experi
drug dialysi set
like close clinic section updat relat recent progress calcimimet
transit start januari implement medicar reimburs oral sensipar
new iv calcimimet call parsabiv transit drug add-on payment adjust
calcimimet prescrib dialysi patient control secondari hyperparathyroid
drug import therapi manag bone miner health transit continu
manag well clinic oper alway physician choic write prescript
order suppli item physician perspect work best patient
guidanc tdapa
ebitda expect low end guidanc mm due lower
treatment growth expect health plan headwind vs estim consensu
mm time report guidanc contempl potenti upsid
sensipar current gener market
lower estim lower ebitda less nci mm
low end guidanc reflect slower ramp treatment growth increas health plan
expens lower ebitda less nci mm assum
volum upsid contract may conserv
consensu ebitda less nci end treatment base guidanc american renal associ hold inc
lower ebitda less nci mm mm
driver ebitda less nci report ebitda less treatment revenu per treat growth volum volum ramp de novosmircera margin margin improv mircera year transitioncalcimimet rate yoy upsid rate continu one year outsid bundletreat cost wage pressur yoycommerci mix headwind mix stabil contract mm headwind networkintern health increas cost intern health plang initi lobbi lobbi mainli leerink ebitda less headwindstailwindsdriv ebitda less nci report ebitda less assum treatment growth tailwind de novosmedicar rate base per treatment yoymircera margin margin improv mircera year transitioncalcimimet rate yoy upsid rate normal cost wage pressur yoy increas suppli cost increas contract mm headwind leerink ebitda less tailwindsheadwind american renal associ hold inc
cffo yoy due time work capit settlement
posit leverag improv ytd believ elimin legal expens
treatment growth lead acceler capit invest leverag reduct capit
deploy focus larg build-out de novo clinic mainten debt paydown
net leverag came
lower pt pt contempl ev/ebtida
trade consensu ev/ebitda
pt contempl ev ebitda multipl revis ebitda less nci
estim mm
pt contempl ev/ebitda ebitda less nci estim
mm
downsid risk valuat includ
substanti reduct govern reimburs
lower margin shift patient privat insur provid medicar
govern program advers consequ new on-going litig
network contract seek go network
futur unfavor polici chang dialysi
execut challeng adopt mircera calcimimet
pt contempl ev/ebitda recent pe takeout
rang physician servic compani given improv visibl margin expans
opportun lack ed catalyst includ earn resolut aet litig
downsid risk valuat includ
continu shift ambulatori could impact patient volum
pressur birthrat could impact children servic volum
continu anesthesia mix shift medicar could impact margin
medicaid payment may face cut state sponsor face budget pressur
potenti cut medicar physician fee schedul
revenu could advers affect net loss contract
incom statement mm except patient servic oper administr ebitda growth ebitda nci margin net incom incom tax less tax net incom attribut growth margin net outstand earn per growth growth american renal associ hold inc
